LEXX (Lexaria Bioscience) Cyclically Adjusted Revenue per Share: $0.00 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
47 GF Score
Price $3.49
GF Value $5.37
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Cyclically Adjusted Revenue per Share?

Lexaria Bioscience LEXX -10.58% 47 Cyclically Adjusted Revenue per Share is $0.00 as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 47/100 and a GF Value™ of $5.37 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lexaria Bioscience's adjusted revenue per share for the three months ended in May. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in May. 2026.

During the past 12 months, Lexaria Bioscience's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -28.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lexaria Bioscience was -16.60% per year. The lowest was -42.90% per year. And the median was -21.40% per year.

As of today (2026-09-14), Lexaria Bioscience's current stock price is $3.49. Lexaria Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was $0.00. Lexaria Bioscience's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lexaria Bioscience was 64.29. The lowest was 2.48. And the median was 13.46.


Lexaria Bioscience  (NAS:LEXX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lexaria Bioscience was 64.29. The lowest was 2.48. And the median was 13.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lexaria Bioscience Cyclically Adjusted Revenue per Share Related Terms


Lexaria Bioscience Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Cyclically Adjusted Revenue per Share Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.02 3.71 -0.49 1.31 1.34

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.34 0.00 1.35 0.00

LEXX vs TPST, LPCN, CYCN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Cyclically Adjusted PS Ratio falls into.


LEXX
47GF Score
Lexaria Bioscience Corp LEXX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0/134.0005*134.0005
=0.000

Current CPI (May. 2026) = 134.0005.

Lexaria Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.087 101.686 0.115
201611 0.078 101.607 0.103
201702 0.106 102.476 0.139
201705 0.215 103.108 0.279
201708 0.087 103.108 0.113
201711 0.163 103.740 0.211
201802 1.103 104.688 1.412
201805 0.886 105.399 1.126
201808 0.593 106.031 0.749
201811 0.130 105.478 0.165
201902 0.088 106.268 0.111
201905 0.335 107.927 0.416
201908 0.714 108.085 0.885
201911 0.057 107.769 0.071
202002 0.213 108.559 0.263
202005 0.195 107.532 0.243
202008 0.670 108.243 0.829
202011 1.480 108.796 1.823
202102 0.711 109.745 0.868
202105 0.600 111.404 0.722
202108 0.086 112.668 0.102
202111 0.037 113.932 0.044
202202 0.079 115.986 0.091
202205 0.252 120.016 0.281
202208 0.280 120.569 0.311
202211 0.247 121.675 0.272
202302 0.050 122.070 0.055
202305 0.182 124.045 0.197
202308 0.057 125.389 0.061
202311 0.250 125.468 0.267
202402 0.202 125.468 0.216
202405 0.091 127.601 0.096
202408 0.080 127.838 0.084
202411 0.166 127.838 0.174
202502 0.149 128.786 0.155
202505 0.143 129.813 0.148
202508 0.133 130.208 0.137
202511 0.000 130.682 0.000
202602 0.012 131.077 0.012
202605 0.000 134.001 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Lexaria Bioscience (LEXX) has a Cyclically Adjusted Revenue per Share of $0.00 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Cyclically Adjusted Revenue per Share too high?
Lexaria Bioscience's current Cyclically Adjusted Revenue per Share is $0.00. Overall, Lexaria Bioscience has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Cyclically Adjusted Revenue per Share compare to TPST and LPCN?
Lexaria Bioscience's Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.37, compared to a current price of $3.49 — trading 35% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.00. Lexaria Bioscience's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Cyclically Adjusted Revenue per Share is $0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $3.49 is trading 35% below its estimated GF Value™ of $5.37. GuruFocus considers Lexaria Bioscience to be Possible Value Trap.

Key valuation signals for LEXX:

  • Cyclically Adjusted Revenue per Share: $0.00
  • GF Value™: $5.37 vs. price of $3.49 (35% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
47GF Score

Get the complete analysis for LEXX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.49
Price
$5.37
GF Value